



GODAVARI DRUGS LIMITED

Regd. Off.: 'Mayfair', S.P. Road, Secunderabad - 500 003. TS, India.

Voice : +91-40-2784 9700 / 2784 2602 / 2784 4557

E-mail : info@godavaridrugs.com | Website : www.godavaridrugs.com

14.11.2024

To,
The Manger [Listing]
The BSE Limited
The Secretary, Listing Department
Phirozejeejeebhoy Towers,
Dalal Street, Fort,
Mumbai- 400001
Scrip code: 530317

Dear Sirs/Madam,

Sub: Submission of Un-Audited Financial Results of the Company and Limited Review Report as per the provisions of Regulation 33 of SEBI (LODR) Regulations, 2015

Please find the enclosed herewith the following documents in terms of Regulation 33 of SEBI (LODR) Regulations, 2015:

1. Un-audited Financial Results of the Company for the quarter and half year ended 30th September, 2024.
2. A certified copy of Limited Review Report on standalone financials for the quarter and half year ended 30th September, 2024 given by the statutory auditors.

These are also being made available on the website of the Company at www.godavaridrugs.com.

The Board Meeting Commenced at 03:00 P.M and concluded at 04:40 PM

Please take the above in your records.

Thanking You,
For Godavari Drugs Limited

Venkatesh Achanta
Company Secretary & Compliance Officer

GODAVARI DRUGS LIMITED

CIN : L24230TG1987PLC008015

Regd Office : " Mayfair" S,P. Road,, Secunderabad

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2024


(in Rs. Lakhs)


SI N	Particulars	Quarter ended			Half Year ended		Year ended
		30.09.2024	30.06.2024	30.09.2023	30.09.2024	30.09.2023	31.03.2024
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Revenue from operations	2608.79	3220.75	3954.25	5829.54	7496.13	15671.19
2	Other Income	0.94	76.51	0.35	77.45	45.56	61.75
3	Total Revenue from operations (1+2)	2609.73	3297.26	3954.60	5906.99	7541.69	15732.94
4	Expenses						
	(a) Cost of materials consumed	1697.53	2694.83	3035.42	4392.36	5679.76	12194.76
	(b) Changes in inventories of finished goods & work-in-progress	59.25	-354.06	40.27	-294.81	202.60	-113.67
	(c) Employee benefits expense	137.91	126.43	119.06	264.34	241.01	513.05
	(d) Depreciation & amortization expense	58.22	54.96	49.38	113.18	96.76	199.46
	(e) Finance Costs	107.98	143.52	129.81	251.50	240.79	491.50
	(f) Other Expenses	423.63	430.37	453.23	854.00	841.62	1746.62
	Total expenses	2484.52	3096.05	3827.17	5580.57	7302.54	15031.72
5	Profit before exceptional Items and tax (3-4)	125.21	201.21	127.43	326.42	239.15	701.22
6	Exceptional items						-9.04
7	Profit before Tax (5-6)	125.21	201.21	127.43	326.42	239.15	692.18
8	Tax expense	-16.35	-38.13	-41.85	-54.48	-72.53	-137.28
9	Net Profit for the period (7-8)	108.86	163.08	85.58	271.94	166.62	554.90
10	Other Comprehensive Income						-
	(i) Items that will not be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to Items that will not be reclassified to profit or loss	-	-	-	-	-	-
	(iii) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(iv) Income tax relating to Items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total Other Comprehensive Income (Net of Tax)	-	-	-	-	-	-
11	Total Comprehensive Income (9+10)	108.86	163.08	85.58	271.94	166.62	554.90
12	Paid-up equity share capital (Face Value Rs. 10/- per share)	753.05	753.05	753.05	753.05	753.05	753.05
13	Other Equity						3143.56
14	Earnings per share (of Rs. 10/- each) (not annualized)						
	(a) Basic	1.45	2.17	1.14	3.61	2.21	7.37
	(b) Diluted	1.45	2.17	1.14	3.61	2.21	7.37

Notes:

- 1) The above results , as reviewed by the Audit Committee, were considered, approved and taken on record by the Board of Directors at its meeting held on 14th November, 2024.
- 2) The above results were prepared in accordance with Indian Accounting Standards (IND AS) prescribed under section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.
- 3) The format for un-audited quarterly results as prescribed in SEBI's Circular No. CIR/CFD/CMD/15/2015 dated 30th November, 2015 has been modified to comply with requirements of SEBI's Circular dated 5th July, 2016. Ind AS Schedule III (Division II) to the Companies Act, 2013 applicable to companies that are required to comply with IND AS.
- 4) Corresponding figures in previous year / period have been regrouped wherever considered necessary.

For GODAVARI DRUGS LIMITED


 Mohit Jaju
 Wholtime Director & CFO
 DIN: 03405414



Place: Secunderabad

Date : 14.11.2024


GODAVARI DRUGS LIMITED
CIN NO.L24230TG1987PLC008016
Regd. Office : - "Mayfair", S.P.Road, Secunderabad.

Statement of Assets and Liabilities

(Rs. In Lakhs)

Particulars	Half Year ended	Year ended
	30.09.2024 (Unaudited)	31.03.2024 (Audited)
ASSETS		
1. Non-current assets		
(a) Property, Plant and Equipment	3425.18	2668.39
(b) Capital work-in-progress	1844.15	1832.06
(c) Investment Property		
(d) Goodwill		
(e) Other Intangible assets		
(f) Intangible assets under development		
(g) Biological Assets other than bearer plant		
(h) Financial Assets		
(i) Investments	0.01	0.01
(ii) Trade Receivables		
(iii) Loans		
(iv) Other (to be specified)	148.71	126.72
(i) Deferred tax assets (net)		
(j) Other non-current assets		
2. Current assets		
(a) Inventories	2021.64	2065.04
(b) Financial Assets		
(i) Investments		
(ii) Trade Receivables	4448.84	5942.33
(iii) Cash and cash equivalents	297.84	262.29
(iv) Bank balances other than (iii) above		
(v) Loans	92.40	89.49
(vi) Other (to be specified)	470.54	488.92
(c) Loans		
(d) Other current assets		
Total Assets	12749.31	13475.25
EQUITY AND LIABILITIES		
EQUITY		
(a) Equity Share Capital	753.05	753.05
(b) Other Equity	3415.50	3143.56
LIABILITIES		
1. Non-current assets		
(a) Financial Liabilities		
(i) Borrowings	1979.01	1116.74
(ii) Trade Payable		
(iii) Other financial liabilities (other than those specified in item (b), to be specified)		
(b) Provisions	81.01	75.57
(c) Defferred Tax liabilities (net)	186.33	186.33
(d) Other non-current liabilities		
2. Current liabilities		
(a) Financial Liabilities		
(i) Borrowings	3903.99	4445.74
(ii) Trade Payable	1651.98	3162.72
(iii) Other financial liabilities (other than those specified in item (c),	717.67	476.00
(b) Other current liabilities	6.29	
(c) Provisions		
(d) Current Tax Liabilities (net)	54.48	115.54
Total Equity and Liabilities	12749.31	13475.25

For GODAVARI DRUGS LIMITED


Mohit Jaju

Wholetime Director & CFO
DIN: 03405414

Place: Secunderabad
Date : 14.11.2024



GODAVARI DRUGS LIMITED
CIN NO.L24230TG1987PLC008016
Regd. Office : - "Mayfair", S.P.Road, Secunderabad.

CASH FLOW STATEMENT FOR THE HALF YEAR ENDED SEPTEMBER 30, 2024

(In Rs. Lakhs)

Particulars	Half Year ended 30.09.2024 (Unaudited)	Yeare ended 31.03.2024 (Audited)
A. Cash Flow from Operating Activities		
Profit before Depreciation, Interest and Tax	691.10	1,383.13
Less : Other Income considered separately	(77.45)	(61.75)
Net	613.65	1,321.38
(Increase) / Decrease in Inventories	43.40	(79.49)
(Increase) / Decrease in Receivables	1,493.49	(148.83)
(Increase) / Decrease in Short term loans & Advances	(2.90)	(0.73)
(Increase) / Decrease in Others	18.38	35.37
Increase / (Decrease) in Current Liabilities	(1,804.53)	815.33
Income Tax Paid	(115.54)	(101.67)
Total A	245.95	1,841.36
B. Cash Flow from Investing Activities		
(Increase)/Decrease in Fixed Assets	(882.06)	(1,320.14)
(Increase)/Decrease in Non current assets	(21.99)	(82.54)
Sale of retired fixed assets (scraoe)		18.77
Other Income	77.45	61.75
Total B	(826.60)	(1,322.16)
C. Cash Flow from Financing Activities		
Increase/(Decrease) in Long Term Borrowings	862.27	(78.01)
Increase/(Decrease) in Provisions	5.43	4.13
Interest paid	(251.50)	(491.49)
Total C	616.20	(565.37)
D. Net Increase/(Decrease) in cash and cash equivalents [A+B+C]	35.55	(46.17)
Cash and cash equivalents at the beginning of the year	262.29	308.46
Cash and cash equivalents at the end of the Period	297.84	262.29
Increase/(-)Decrease	35.55	(46.17)

For GODAVARI DRUGS LIMITED


Mohit Jaju
Wholetime Director & CFO
DIN: 03405414



Place: Secunderabad
Date : 14.11.2024

Independent Auditor's Review Report on unaudited quarterly and year to date financial results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015


To,
The Board of Directors,
Godavari Drugs Limited
Secunderabad.

We have reviewed the accompanying statement of unaudited financial results of Godavari Drugs Limited (the Company) for the quarter ended 30th September, 2024 (the statement). This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Ayyadevara & Co.,
Chartered Accountants
FRN: 002785



Ayyadevara Srinivas
Proprietor
Membership No.028803
Secunderabad, Date :14/11/2024.
UDIN: 24028803BKHJHQ2737

